These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical Characteristics of an Italian Patient Population with Advanced BCC and Real-Life Evaluation of Hedgehog Pathway Inhibitor Safety and Effectiveness. Mannino M; Piccerillo A; Fabbrocini G; Quaglino P; Argenziano G; Dika E; Ascierto PA; Pellacani G; Longo C; Fargnoli MC; Bianchi L; Calzavara-Pinton P; Zalaudek I; Fava P; Scalvenzi M; Bocchino E; Di Stefani A; Peris K; Dermatology; 2023; 239(6):868-876. PubMed ID: 37311439 [TBL] [Abstract][Full Text] [Related]
4. Switching Hedgehog inhibitors and other strategies to address resistance when treating advanced basal cell carcinoma. Doan HQ; Chen L; Nawas Z; Lee HH; Silapunt S; Migden M Oncotarget; 2021 Sep; 12(20):2089-2100. PubMed ID: 34611482 [TBL] [Abstract][Full Text] [Related]
5. Supraorbital Basosquamous Carcinoma Treated with Cemiplimab Followed by Sonidegib: A Case Report and Review of the Literature. Proietti I; Filippi L; Tolino E; Bernardini N; Svara F; Trovato F; Di Cristofano C; Petrozza V; Bagni O; Vizzaccaro A; Skroza N; Potenza C Biomedicines; 2023 Oct; 11(11):. PubMed ID: 38001904 [No Abstract] [Full Text] [Related]
6. Pharmacokinetics and pharmacodynamics of Hedgehog pathway inhibitors used in the treatment of advanced or treatment-refractory basal cell carcinoma. Lear JT; Morris LM; Ness DB; Lewis LD Expert Rev Clin Pharmacol; 2023; 16(12):1211-1220. PubMed ID: 37975712 [TBL] [Abstract][Full Text] [Related]
7. Systemic Targeted Treatments for Basal Cell Carcinoma. Svoboda SA; Johnson NM; Phillips MA Cutis; 2022 Jun; 109(6):E25-E31. PubMed ID: 35960978 [TBL] [Abstract][Full Text] [Related]
8. Using drug scheduling to manage adverse events associated with hedgehog pathway inhibitors for basal cell carcinoma. Lear JT; Dummer R; Guminski A Oncotarget; 2021 Dec; 12(26):2531-2540. PubMed ID: 34966484 [TBL] [Abstract][Full Text] [Related]
9. The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): A phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma. Dummer R; Guminski A; Gutzmer R; Dirix L; Lewis KD; Combemale P; Herd RM; Kaatz M; Loquai C; Stratigos AJ; Schulze HJ; Plummer R; Gogov S; Pallaud C; Yi T; Mone M; Chang AL; Cornélis F; Kudchadkar R; Trefzer U; Lear JT; Sellami D; Migden MR J Am Acad Dermatol; 2016 Jul; 75(1):113-125.e5. PubMed ID: 27067394 [TBL] [Abstract][Full Text] [Related]
10. The association of cemiplimab plus sonidegib for synchronous cutaneous squamous cell carcinoma and basal cell carcinoma of the head and neck: Two case reports. Colombo E; Gurizzan C; Ottini A; Caspani F; Bergamini C; Locati LD; Marchiselli C; Alberti A; Lorini L; Licitra LF; Bossi P; Resteghini C Front Oncol; 2023; 13():1111146. PubMed ID: 36925925 [TBL] [Abstract][Full Text] [Related]